{'fraction_non_alphanumeric': 0.02867383512544803, 'fraction_numerical': 0.007168458781362007, 'mean_word_length': 5.758064516129032, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
POPULATION‐BASED OUTCOMES IN LARGE B‐CELL LYMPHOMA BY WHO SUBTYPE: FINDINGS FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK

reactive BCRs. Moreover, the BCR binding epitope of neurabin-I conjugated to truncated Pseudomonas exotoxin A killed lymphoma cells expressing the respective BCRs. Conclusion: Our results support the role of chronic antigenic stimulation by speicific and posttranslationally modified autoantigens in the pathogenesis of a subgroup of PCNSL. Studies on the frequency of hyper-N-glyocsylated SAMD14/neurabin-I isoforms and of SAMD14/neurabin-I autoantibodies in prospectively collected sera of patients from PCNSL rials are necessary to better determine the “real” proportion of the SAMD14/neurabin-I-reactive subgroup in PCNSL. Finally, different therapeutic concepts for this subgroup will be presented.